再生元制药

Regeneron's 15-minute chart triggers KDJ Golden Cross, bullish Marubozu formation detected.

Regeneron

Regeneron Pharmaceuticals Takes Over #42 Spot from Corteva in Analyst Rankings

Regeneron Pharmaceuticals: A Bullish Thesis on Diversified Growth Potential and Robust Pipeline

Regeneron's 15min chart triggers Bollinger Bands Narrowing and Bearish Marubozu.

Sanofi

Regeneron's 2026 Outlook: Balanced with Dupixent Growth and Sanofi Collaboration

Catalyst<ul> <li>Most analysts rate REGN Buy or Strong Buy, showing broad institutional optimism.</li></ul>Risk<ul> <li>Technical indicators show that the market is in a weak state and we need to pay attention to the risk of decline.</li> <li>Bearish signals are obviously dominant with 2 bearish vs 0 bullish technical signals.</li></ul>

Key Factors

Regeneron Pharmaceuticals (REGN) experienced a 1.09% stock decline on February 5, 2026, with a trading volume of $0.75 billion. REGN announced a 6.8% increase in its quarterly dividend to $0.94 per share in February 2026, signaling confidence in future cash flow. Regeneron surpassed Corteva Inc to take the #42 spot in S&P 500 analyst rankings based on average opinions from major brokerage houses.

Recent Updates

REGN News